p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy

Dong Hu, Xiaoshuang Lyu, Zheqi Li, Prasanna Ekambaram, Anushka Dongre, Tanner J. Freeman, Marion Joy, Jennifer M. Atkinson, Daniel D. Brown, Zongyou Cai, Neil Carleton, Hannah E. Crentsil, John R. Little, Felicia Kemp, Linda R. Klei, Maria Beecher, Jeff Sperinde, Weidong Huang, Heikki Joensuu, Ashok Srinivasan, Katherine L. Pogue–Geile, Ying Wang, Huichen Feng, Lisa D. Eli, Alshad S. Lalani, Jian Zou, George C. Tseng, Tullia C. Bruno, Adrian V. Lee, Steffi Oesterreich, Norman Wolmark, Carmen J. Allegra, Samuel A. Jacobs, Linda M. McAllister‐Lucas, Peter C. Lucas